Literature DB >> 3124195

The economic cost of senile dementia in the United States, 1985.

L F Huang1, W S Cartwright, T W Hu.   

Abstract

Senile dementia is a progressive and irreversible decline of mental functions. The symptoms are mental confusion, memory loss, disorientation, cognitive decline, and inappropriate social behavior. It is one of the most common, costly, and distressful diseases among the elderly in the United States. Information on the economic costs of senile dementia is essential for determining research priorities and the allocation of resources to support aging and medical research. Economic consequences, such as direct medical and nonmedical expenditures by patients' families and the amount of time by third parties in caring for patients with senile dementia, are substantial. However, little systematic accounting to estimate these consequences has been undertaken. This paper attempts to estimate various costs associated with the care of senile dementia, based on available secondary data. We have used the direct cost and indirect cost approach and avoided double counting to identify the additional economic costs due to senile dementia. The total, direct national cost of senile dementia is $13.26 billion, which includes $6.36 billion of medical care costs, $2.56 billion of nursing home care costs, and $4.34 billion of social agency service costs. The indirect cost for community home care alone is $31.46 billion, more than twice the total direct costs. The costs of premature death and loss of productivity due to senile dementia are about $43.17 billion. Although most of the indirect costs were imputed from the value of housekeeping or productivity loss, the magnitude of indirect costs reflects the serious consequences and burden on society's resources of this disease.

Entities:  

Mesh:

Year:  1988        PMID: 3124195      PMCID: PMC1477951     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  6 in total

1.  Evaluation of the costs of caring for the senile demented elderly: a pilot study.

Authors:  T W Hu; L F Huang; W S Cartwright
Journal:  Gerontologist       Date:  1986-04

2.  Caregiver well-being: a multidimensional examination of family caregivers of demented adults.

Authors:  L K George; L P Gwyther
Journal:  Gerontologist       Date:  1986-06

3.  Observations on the brains of demented old people.

Authors:  B E Tomlinson; G Blessed; M Roth
Journal:  J Neurol Sci       Date:  1970-09       Impact factor: 3.181

4.  An overview of current concepts of Alzheimer's disease.

Authors:  M K Schneck; B Reisberg; S H Ferris
Journal:  Am J Psychiatry       Date:  1982-02       Impact factor: 18.112

5.  The economic value of life: linking theory to practice.

Authors:  J S Landefeld; E P Seskin
Journal:  Am J Public Health       Date:  1982-06       Impact factor: 9.308

6.  The economic costs of illness: a replication and update.

Authors:  D P Rice; T A Hodgson; A N Kopstein
Journal:  Health Care Financ Rev       Date:  1985
  6 in total
  18 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis.

Authors:  R C Dodel; M Singer; R Köhne-Volland; T Szucs; B Rathay; E Scholz; W H Oertel
Journal:  Pharmacoeconomics       Date:  1998-09       Impact factor: 4.981

Review 3.  The cost of Alzheimer's disease. Will drug treatment ease the burden?

Authors:  W Max
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

4.  National spending on mental health and substance abuse treatment by age of clients, 1997.

Authors:  Henrick J Harwood; Tami L Mark; David R McKusick; Rosanna M Coffey; Edward C King; James S Genuardi
Journal:  J Behav Health Serv Res       Date:  2003 Oct-Dec       Impact factor: 1.505

5.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

6.  [Psychiatry in transitions of the public health system].

Authors:  H Helmchen
Journal:  Nervenarzt       Date:  2004-11       Impact factor: 1.214

Review 7.  A systematic review to assess the policy-making relevance of dementia cost-of-illness studies in the US and Canada.

Authors:  Mark Oremus; S Carolina Aguilar
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

Review 8.  The pharmacoeconomics of dementia therapies. Bringing the clinical, research and economic perspectives together.

Authors:  F J Molnar; W B Dalziel
Journal:  Drugs Aging       Date:  1997-03       Impact factor: 3.923

9.  Sensitivity of nursing home cost comparisons to method of dementia diagnosis ascertainment.

Authors:  Ann L Gruber-Baldini; Bruce Stuart; Ilene H Zuckerman; Van Doren Hsu; Kenneth S Boockvar; Sheryl Zimmerman; Steven Kittner; Charlene C Quinn; J Richard Hebel; Conrad May; Jay Magaziner
Journal:  Int J Alzheimers Dis       Date:  2009-09-22

Review 10.  Economic considerations in the management of Alzheimer's disease.

Authors:  Carolyn W Zhu; Mary Sano
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.